Fogacci, Federica

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Hay, S. I., Ong, K. L., Santomauro, D. F., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abate, B. B., Abbafati, C., et al. (2025) · The Lancet

Global Health and EpidemiologyCardiovascular Health and Risk Factors

Cited by 916

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Naghavi, M., Kyu, H. H., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abafita, B. J., Abaraogu, U. O., Abbafati, C., Abbasi, M., et al. (2025) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Health and Epidemiology

Cited by 595

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 132

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?

Cicero, A. F. G., Fogacci, F., Stoian, A. P., Vrablik, M., Al Rasadi, K., Banach, M., Toth, P. P., & Rizzo, M. (2021) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthNatural Products and Biological Research

Cited by 110

A Randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT) Study

Cicero, A. F. G., Fogacci, F., Veronesi, M., Strocchi, E., Grandi, E., Rizzoli, E., Poli, A., Marangoni, F., & Borghi, C. (2020) · Nutrients

Food composition and propertiesMicrobial Metabolites in Food Biotechnology

Cited by 106

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials

Fogacci, F., Grassi, D., Rizzo, M., & Cicero, A. F. G. (2019) · Phytotherapy Research

Berberine and alkaloids researchNatural Antidiabetic Agents Studies

Cited by 61

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 54

Three‐arm, placebo‐controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects

Cicero, A. F. G., Fogacci, F., Bove, M., Giovannini, M., & Borghi, C. (2019) · Phytotherapy Research

Natural Products and Biological ResearchNatural Antidiabetic Agents Studies

Cited by 51

Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial

Cicero, A. F. G., Fogacci, F., Rosticci, M., Parini, A., Giovannini, M., Veronesi, M., D’Addato, S., & Borghi, C. (2017) · Nutrition & Metabolism

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 41

Arterial Stiffness, Sugar-Sweetened Beverages and Fruits Intake in a Rural Population Sample: Data from the Brisighella Heart Study

Cicero, A. F. G., Fogacci, F., Desideri, G., Grandi, E., Rizzoli, E., D’Addato, S., & Borghi, C. (2019) · Nutrients

Cardiovascular Health and Disease PreventionDiet, Metabolism, and Disease

Cited by 37

Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial

Cicero, A. F. G., Colletti, A., Fogacci, F., Bove, M., Rosticci, M., & Borghi, C. (2017) · High Blood Pressure & Cardiovascular Prevention

Natural Products and Biological ResearchLipoproteins and Cardiovascular Health

Cited by 35

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies

Cicero, A. F. G., Fogacci, F., Zambon, A., Toth, P. P., & Borghi, C. (2022) · American Heart Journal Plus: Cardiology Research and Practice

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 34

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk

Silla, A., Fogacci, F., Punzo, A., Hrelia, S., Simoni, P., Caliceti, C., & Cicero, A. F. G. (2023) · Antioxidants

Lipoproteins and Cardiovascular HealthCardiovascular Health and Disease Prevention

Cited by 25

Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic

Cicero, A. F. G., Morbini, M., Bove, M., D’Addato, S., Fogacci, F., Rosticci, M., & Borghi, C. (2016) · Current Medical Research and Opinion

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 23

Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

Cicero, A. F. G., Kennedy, C., Knežević, T., Bove, M., Georges, C. M. G., Šatrauskienė, A., Toth, P. P., & Fogacci, F. (2021) · Nutrients

Natural Products and Biological ResearchLipoproteins and Cardiovascular Health

Cited by 20

Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab

Fogacci, F., Yerlitaş, S. İ., Giovannini, M., Zararsız, G., Lido, P., Borghi, C., & Cicero, A. F. G. (2023) · Biomedicines

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 15